v3.26.1
Segment Information - Schedule of Significant Expense Categories and Amounts Align with Segment-Level Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:            
Collaboration revenue $ 6,314   $ 10,130   $ 13,538 $ 18,948
Operating expenses:            
Research and development personnel-related (excluding stock-based compensation) 20,405   19,279   40,218 37,290
External research and development costs - GB-0895 20,490   13,280   36,076 17,074
External - discovery related costs and other 16,879   21,122   33,337 40,292
General and administrative personnel-related (excluding stock-based compensation) 4,545   4,457   9,185 8,888
External - General and administrative 4,147   3,332   9,318 6,740
Stock-based compensation 8,238   5,487   14,633 10,231
Depreciation expense 3,224   3,322   6,497 6,736
Other segment expenses 62   31   367 48
Interest income (4,629)   (3,789)   (7,542) (8,070)
Interest expense 155   307   337 675
Provision for income tax 53   44   81 100
Net loss (67,255)   (56,742)   (128,969) (101,056)
Net loss attributable to non-controlling interests 0   (4,313)   (268) (6,942)
Net loss attributable to Generate Biomedicines, Inc. stockholders $ (67,255) $ (61,446) $ (52,429) $ (41,685) $ (128,701) $ (94,114)